According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. “
A number of other analysts have also recently weighed in on the stock. Roth Capital decreased their target price on shares of Diamondback Energy from $166.00 to $150.00 and set a buy rating on the stock in a research note on Friday, June 7th. BidaskClub cut shares of Waterstone Financial from a hold rating to a sell rating in a research note on Friday, June 21st. Leerink Swann assumed coverage on shares of Affimed in a research note on Thursday, March 28th. They set an outperform rating and a $4.17 target price on the stock. Svb Leerink assumed coverage on shares of Fate Therapeutics in a research note on Thursday, March 28th. They set an outperform rating and a $20.00 target price on the stock. Finally, Piper Jaffray Companies cut shares of Pioneer Energy Services from an overweight rating to a neutral rating in a research note on Thursday, June 27th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $22.77.
NASDAQ FATE opened at $21.54 on Wednesday. The business’s fifty day moving average is $19.49. The company has a market capitalization of $1.33 billion, a PE ratio of -18.10 and a beta of 1.65. Fate Therapeutics has a fifty-two week low of $8.64 and a fifty-two week high of $22.61. The company has a current ratio of 6.40, a quick ratio of 6.40 and a debt-to-equity ratio of 0.26.
Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). The company had revenue of $2.63 million for the quarter, compared to the consensus estimate of $2.01 million. Fate Therapeutics had a negative return on equity of 54.30% and a negative net margin of 1,138.12%. The business’s quarterly revenue was up 156.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.27) EPS. As a group, analysts expect that Fate Therapeutics will post -1.29 EPS for the current year.
In related news, insider Daniel D. Shoemaker sold 12,500 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $20.21, for a total value of $252,625.00. Following the transaction, the insider now owns 148,091 shares in the company, valued at $2,992,919.11. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO J Scott Wolchko sold 8,541 shares of the business’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $16.17, for a total transaction of $138,107.97. Following the completion of the transaction, the chief executive officer now owns 375,973 shares in the company, valued at approximately $6,079,483.41. The disclosure for this sale can be found here. In the last three months, insiders sold 35,376 shares of company stock worth $668,402. 23.19% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. lifted its holdings in Fate Therapeutics by 248.5% in the first quarter. Meeder Asset Management Inc. now owns 2,826 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 2,015 shares during the period. SG Americas Securities LLC bought a new stake in shares of Fate Therapeutics during the first quarter worth about $169,000. Legal & General Group Plc increased its position in shares of Fate Therapeutics by 48.6% during the fourth quarter. Legal & General Group Plc now owns 11,376 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 3,719 shares in the last quarter. BNP Paribas Arbitrage SA bought a new stake in shares of Fate Therapeutics during the first quarter worth about $221,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Fate Therapeutics by 9.9% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,624 shares of the biopharmaceutical company’s stock worth $222,000 after acquiring an additional 1,139 shares in the last quarter. Institutional investors and hedge funds own 93.28% of the company’s stock.
About Fate Therapeutics
Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.
Featured Article: Forex
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.